A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI (Formoterol Fumarate) in Asthmatic Subjects

Trial Profile

A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI (Formoterol Fumarate) in Asthmatic Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Formoterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms FLASH
  • Sponsors Chiesi Farmaceutici SpA
  • Most Recent Events

    • 01 Aug 2018 Status changed from active, no longer recruiting to completed.
    • 20 Apr 2018 Planned End Date changed from 30 Apr 2018 to 30 Jul 2018.
    • 20 Apr 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top